This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Revisiting Monoamine Oxidase Inhibitors

K. Ranga Krishnan, MD

Published: July 16, 2007

Article Abstract

Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatmentof depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorablesafety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. Thedevelopment of a novel, transdermal MAOI system now offers clinicians an additional option for managingpatients with unipolar, bipolar, atypical, and treatment-resistant depression.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: Psychopharmacology

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...